Modernatx, Inc.

Vanderbilt University

Sunny Himansu

Giuseppe Ciaramella

Eric Yi-Chun Huang

Tal Zaks

Sayda Mahgoub Elbashir

Kapil Bahl

Kerry Benenato

Vladimir Presnyak

Ellalahewage Sathyajith Kumarasinghe

James E Crowe, Jr

Tai Zaks

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to mRNA betacoronavirus vaccines formulated in a lipid nanoparticle.

Betacoronavirus mRNA vaccines

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

Betacorona virus mRNA vaccines

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Betacoronavirus MRNA vaccines

Betacoronavirus RNA vaccines

Combination HMPV/RSV RNA vaccines

This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject. Compositions and treatments provided herein include one or more polynucleotides having an open reading frame encoding an anti-chikungunya virus antibody heavy chain or fragment thereof and/or an anti-chikungunya virus antibody light chain or fragment thereof. Methods for preparing and using such treatments are also provided.

Polynucleotides encoding anti-chikungunya virus antibodies

Provide herein are Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.

Zoonotic disease RNA vaccines

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.

CHIKV RNA vaccines

The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.

Zika virus RNA vaccines

Chikungunya virus RNA vaccines

Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.

Zika virus mRNA vaccines

Provided herein, in some embodiments, are vaccines (and vaccination methods) that include a ribonucleic acid (RNA) polynucleotide encoding a human metapneumovirus (hMPV) F protein and a RNA polynucleotide encoding a human parainfluenza virus 3 (hPrV3) F protein.

Growing community of inventors

Winchester, MA, United States of America

Sunny Himansu